View of VALUATION OF THE CT LI-RADS TREATMENT RESPONSE V2018 IN PATIENTS AFTER FIRST-LINE DEB-TACE) FOR HEPATOCELLULAR CARCINOMA (HCC)

Return to Article Details VALUATION OF THE CT LI-RADS TREATMENT RESPONSE V2018 IN PATIENTS AFTER FIRST-LINE DEB-TACE) FOR HEPATOCELLULAR CARCINOMA (HCC) Download Download PDF